Enjoy complimentary customisation on priority with our Enterprise License!
The pulmonary embolism therapeutics market size is forecast to increase by USD 14.02 billion at a CAGR of 10.93% between 2023 and 2028. The pulmonary embolism therapeutics market is experiencing significant growth due to the increasing risk of adverse health conditions, such as deep vein thrombosis and PE, which can lead to serious complications and even death if left untreated. Additionally, advancements in the healthcare and medical sector, including the development of new medical technologies and therapeutic approaches, are driving market growth. However, the market faces challenges due to the potential adverse effects of therapeutics, such as bleeding risks associated with anticoagulant therapies and the need for close monitoring and careful dosing. Despite these challenges, the market is expected to continue growing due to the high unmet medical needs related to thrombosis drugs and the ongoing research and development efforts in the field.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Route of Administration
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.